CD8A and cancer: With potential neoantigens related gene aberrations, combinatorial therapies, including immune modulation, are expected to give better survival over the current standard of care.40,41 In clinical cases, it is reported that an elevated level of tumor-infiltrating immune cells, such as anti-cancer CD8+ T-cells, correlates with prolonged survival in GBM patients.32